News Releases

Year

March 31, 2023

Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up

New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic Biology Workstation SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions,

March 21, 2023

Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance

-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21 -- BioXp ® Revenue increased by 158% to $3.4M, in 4QFY22 over 4QFY21 SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported

March 16, 2023

Telesis Bio to Present at Festival of Biologics Conference

Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic

March 14, 2023

Telesis Bio to Present at RNA Leaders Europe Congress

Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their benchtop automation

March 9, 2023

Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.

February 27, 2023

Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will participate in a fireside chat with Steven Mah at the 43rd Annual

February 16, 2023

Telesis Bio Releases BioXp® Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation

Scientists Can Now Begin the mRNA Synthesis Process from Their Own Sequence or Plasmid DNA SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the availability of its BioXp® Select mRNA

January 9, 2023

Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp ® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio’s SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan.

First page
Previous page
Page 1
Current page 2

Displaying 11 - 18 of 18

Investor Relations

News & Events menu